Prevalence of unmet target LDL-C recommendations in very high risk patients despite high intensity lipid modifying therapy

Phase 4

Completed

• Conditions: Hyperlipidaemia/ high cholesterol post myocardial infarction; 10003216

• Registration Number: NL-OMON55816
• Lead Sponsor: WCN (Werkgroep Cardiologische centra Nederland)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Last Update Posted: 15 April 2024

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 1000

Inclusion Criteria

- Admission because of type I (N)STEMI, and
- History of ASCVD (i.e., cerebrovascular disease (Transient ischemic attack,
cerebral infarction, amaurosis fugax, retinal infarction), Coronary artery
disease (unstable Angina pectoris, MI, ACS, coronary revascularization
(coronary angioplasty or surgical procedure for coronary bypass)), Peripheral
artery disease (Symptomatic and documented obstruction of an distal extremity
artery or surgical operation (percutaneous transluminal angioplasty, bypass or
amputation), and/or a history of T2DM.

Exclusion Criteria

- Age <18 years
- Age >70 years ánd a Clinical Frailty Score >3.
o To measure the frailty score, the validated Dutch translation of the Canadian
Study of Health and Aging (CSHA) Clinical Frailty Scale will be used (table 2)
- Pregnancy and lactating women
- Known intolerance for alirocumab
- Active PCSK9-i therapy
- Participation in lipid modifying drug trials
- Life expectancy <1 yr.

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
<p>Study endpoint:<br /><br><br /><br>- Proportion of patients with LDL-C >1.8 mMol/L during stepwise incremental<br /><br>lipid modifying therapy with respectively a statin, statin + ezetimibe. </p><br>